// App-Quantinova.ai

PO0562 : Switching from Agalsidase Alfa to Pegunigalsidase Alfa for Treating Fabry Disease: One Year of Treatment Data from Bridge, a Phase 3 Open-Label Study

Researchers

Presenter

  • Tndel Camilla

Principal Investigators

  • Linhart Ales

  • Dostlov Gabriela

  • Nicholls KathleenM

  • West MichaelL

  • Jovanovic Ana

  • Giraldo Pilar

  • Vujkovac Bojan

  • Almon Einat

  • Alon Sari

  • Szlaifer Mali

  • Chertkoff Raul

  • Hughes Derralynn

Medical Centers

  • Haukeland University Hospital, Bergen, Norway

  • Charles University, Prague, Czechia

  • The Royal Melbourne Hospital Melbourne Victoria Australia

  • Dalhousie University, Halifax, Nova Scotia, Canada.

  • Salford Royal Dept of Inherited Metabolic Disease Salford United Kingdom

  • Hospital de Dia Quiron Zaragoza Spain

  • General Hospital Slovenj Gradec,Slovenj Gradec,Slovenia

  • Protalix Biotherapeutics Carmiel Northern Israel

  • LSDU Institute of Immunity and Transplantation Royal Free London NHS Foundation Trust London United Kingdom

Locations

  • Norway

  • Czech Republic

  • Australia

  • Canada

  • United Kingdom

  • Spain

  • Slovenia

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Fabry disease

Biomarkers

  • N/A

Drug/Treatment

  • Agalsidase alfa

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved